ANAB
AnaptysBio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$56.80
−1.15%Margins
Gross margin
116.4%
EBITDA margin
25.2%
EBIT margin
17.6%
Net margin
-11.5%
FCF margin
1.9%
-210.1%
Return on equity
-8.1%
Return on assets
14.1%
Return on invested capital
0.67x
Asset turnover
$4.5M
Cash from operations
$9.67
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Mar 1, 2026